Restricted accessBrief reportFirst published online 2016-09
Molecular Genetic Profiling of Adolescent Glassy Cell Carcinoma of the Cervix Reveals Targetable EGFR Amplification with Potential Therapeutic Implications
Glassy cell carcinoma of the cervix (GCCC) is a very rare and aggressive form of cervical cancer. An adolescent female with advanced metastatic disease was enrolled in our genomic profiling research protocol. We identified high-level amplification of epidermal growth factor receptor (EGFR) and Yes-associated protein-1 (YAP1), which led to the addition of EGFR inhibitors to the chemotherapy regimen. Here, we report the first genetically profiled case of GCCC with potential therapeutic implications.
Get full access to this article
View all access options for this article.
References
1.
Zolciak-SiwinskaA, Jonska-GmyrekJ. Glassy cell carcinoma of the cervix: a literature review. Eur J Obstet Gynecol Reprod Biol. 2014; 179:232–5.
2.
HopkinsMP, MorleyGW. Glassy cell adenocarcinoma of the uterine cervix. Am J Obstet Gynecol. 2004; 190(1):67–70.
3.
GuitarteC, AlagkiozidisI, MizeB, et al.Glassy cell carcinoma of the cervix: a systematic review and meta-analysis. Gynecol Oncol. 2014; 133(2):186–91.
4.
MooreKN, HerzogTJ, LewinS, et al.A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007; 105(2):299–303.
5.
TewariKS, SillMW, LongHJ, et al.Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734–43.
6.
PignataS, ScambiaG, KatsarosD, et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014; 15(4):396–405.
7.
KurodaH, ToyozumiY, MasudaT, et al.Glassy cell carcinoma of the cervix: cytologic features and expression of estrogen receptor, progesterone receptor and Her2/neu protein. Acta Cytol. 2006; 50(4):418–22.
8.
LorenzettoE, BrencaM, BoeriM, et al.YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. Oncotarget. 2014; 5(9):2608–21.
9.
KapoorA, YaoW, YingH, et al.Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014; 158(1):185–97.
10.
Hélias-RodzewiczZ, PérotG, ChibonF, et al.YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer. 2010; 49(12):1161–71.
11.
SteinhardtAA, GayyedMF, KleinAP, et al.Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008; 39(11):1582–9.
12.
LeeK-W, LeeSS, KimS-B, et al.Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res. 2015; 21(2):357–64.
13.
JerhammarF, JohanssonA-C, CederR, et al.YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncol. 2014; 50(9):832–9.
14.
WhelerJJ, TsimberidouAM, FalchookGS, et al.Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013; 12(10):2167–75.
15.
WeickhardtAJ, PriceTJ, ChongG, et al.Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol. 2012; 30(13):1505–12.
16.
RosanòL, CianfroccaR, SpinellaF, et al.Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011; 17(8):2350–60.
17.
PolyakK, WeinbergRA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265–73.
18.
MasekiS, IjichiK, TanakaH, et al.Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer. 2012; 106(6):1196–204.
19.
YounisS, JavedQ, BlumenbergM. Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis. BMC Cancer. 2015; 15:369.
20.
WangDD, MaL, WongMP, et al.Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments. PLoS One. 2015; 10(5):e0128360.
21.
IidaM, BrandTM, StarrMM, et al.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014; 13:242.
